In the European pharmaceutical industry, there were 21 private equity deals announced in Q4 2023, worth a total value of $559.2m, according to GlobalData’s Deals Database. The $528.6m Institutional Buy-out (IBO) EUGIN Clinic by GED Capital and KKR was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Europe decreased by 53% in Q4 2023 compared with the previous quarter’s total of $1.2bn and fell by 26% as compared to Q4 2022. Related deal volume increased by 11% in Q4 2023 versus the previous quarter.
The top-ranked financial advisors supporting these private equity deals in Europe in Q4 2023 were Rothschild & Co; PricewaterhouseCoopers International; KPMG International Coop with 7, 5, 4 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Europe Q4 2023 were Baker & McKenzie; Freshfields Bruckhaus Deringer; Gibson, Dunn & Crutcher with 3, 3, 3 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.